Status:

TERMINATED

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

Lead Sponsor:

Idorsia Pharmaceuticals Ltd.

Conditions:

Heart Diseases

Hypertension, Pulmonary

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Endothelin-1 is a powerful substance that may be involved in causing hemodynamic instability (problems related to unstable blood pressure) during and after open heart surgery. Tezosentan is an investi...

Detailed Description

Endothelin-1 levels are increased during and after cardiac surgery with cardiopulmonary bypass (CPB), and are associated with many deleterious consequences, including increased pulmonary arterial pres...

Eligibility Criteria

Inclusion

  • Patients ≥ 18 years of age
  • Male or female patients (females of child-bearing potential must have been surgically sterilized or use a reliable method of contraception).
  • Patients undergoing complex\* cardiac surgery on CPB and having systolic PAP \> 40 mmHg or mean PAP \> 30 mmHg (\*surgery on 2 valves, 1 valve and revascularization, or reoperation of a valve)
  • Patients undergoing cardiac surgery on CPB and having pre-operative pulmonary hypertension due to left heart disease with systolic PAP \> 60 mmHg
  • Signed written informed consent

Exclusion

  • Systolic blood pressure \< 100 mmHg
  • Significant chronic lung disease
  • Emergency surgery
  • Pregnant/breast-feeding
  • Investigational drug use within 28 days prior to randomization
  • Complex adult congenital heart disease.
  • Severe concomitant illness limiting life expectancy to \< 6 months
  • Participation in a device study that will affect the outcome of the study
  • Pre-operative use of balloon pump, inotropes/vasopressors, treatment of pulmonary arterial hypertension
  • Known hypersensitivity to tezosentan or drugs of the same class, or any of their excipients
  • Severe liver impairment

Key Trial Info

Start Date :

April 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2008

Estimated Enrollment :

274 Patients enrolled

Trial Details

Trial ID

NCT00458276

Start Date

April 1 2007

End Date

March 1 2008

Last Update

July 9 2018

Active Locations (33)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (33 locations)

1

Stanford University School of Medicine

Stanford, California, United States, 94305

2

Columbia University Medical Center

New York, New York, United States, 10032

3

Montefiore Medical Center/Albert Einstein College of Medicine

New York, New York, United States, 10467

4

Duke University Medical Center

Durham, North Carolina, United States, 27710